Zacks Research Issues Negative Outlook for AXSM Earnings
Zacks Research has issued a negative outlook for Axsome Therapeutics (NASDAQ:AXSM), reducing its Q1 2027 EPS estimate from $0.92 to $0.75. The consensus for the full-year earnings is projected at ($2.79) per share. Despite this, several analysts have raised their price targets for the stock, with a consensus rating of "Moderate Buy" and an average target price of $169.80. Axsome's stock opened at $98.50, with a market cap of $4.80 billion and a P/E ratio of -16.44.
- 5 medical stocks growing earnings by triple digits
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research reduced their Q1 2027 EPS estimates for Axsome Therapeutics in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.75 per share for the quarter, down from their previous estimate of $0.92. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' FY2027 earnings at $5.37 EPS.
Get Axsome Therapeutics alerts:
Several other equities research analysts also recently commented on AXSM. Bank of America lifted their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Royal Bank of Canada boosted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Needham & Company LLC reissued a "buy" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Robert W. Baird lifted their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Finally, Leerink Partners increased their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $169.80.
- Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Get Our Latest Report on Axsome Therapeutics
Axsome Therapeutics Stock Performance
Shares of Axsome Therapeutics stock opened at $98.50 on Tuesday. The firm has a market capitalization of $4.80 billion, a P/E ratio of -16.44 and a beta of 0.88. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The company has a 50 day moving average price of $120.54 and a 200 day moving average price of $101.85.
- Why this is an Awesome Time to Buy Axsome Therapeutics
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million.
Insiders Place Their Bets
In other news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 22.40% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL lifted its holdings in Axsome Therapeutics by 32.7% during the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Axsome Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after purchasing an additional 4,079 shares during the last quarter. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock valued at $66,750,000 after buying an additional 8,125 shares in the last quarter. Invesco Ltd. boosted its holdings in Axsome Therapeutics by 10.8% in the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company's stock worth $58,589,000 after buying an additional 67,285 shares during the last quarter. Finally, Hood River Capital Management LLC increased its stake in Axsome Therapeutics by 3.2% during the 4th quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock worth $54,555,000 after buying an additional 19,701 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.
Axsome Therapeutics Company Profile
(Get Free Report)Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Recommended Stories
- Five stocks we like better than Axsome Therapeutics
- How to Invest in the FAANG Stocks
- Options Activity Points to More Volatility for Palantir Stock
- What to Know About Investing in Penny Stocks
- NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?
- Best Stocks Under $5.00
- MicroStrategy Sees Insider Buy-Sell Action in Q1
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Axsome Therapeutics Right Now?
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
